CAPR News and Press, Capricor Therapeutics Inc. From 09/08/20

The following slide deck was published by Capricor Therapeutics, Inc. in conjunction with this Read more ...

LOS ANGELES, CA / ACCESSWIRE / August 31, 2020 / LD Micro today announced the final list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online. Registration details and the company schedule can be seen here: https://ld500.ldmicro.co...

LOS ANGELES, CA / ACCESSWIRE / August 31, 2020 / Capricor Therapeutics ("Capricor") (NASDAQ:CAPR), a clinical-stage biotechnology company focused on the development of first-in-class cell and exosome-based therapeutics for the treatment and prevention of diseases, today announced that it w...

Dyne Therapeutics ( DYN ) has filed a preliminary prospectus for a $100M IPO. More news on: Dyne Therapeutics, Inc., Sarepta Therapeutics, Inc., Nippon Shinyaku Co. Ltd., Healthcare stocks news, IPO News, , Read more ...

– The INSPIRE Trial is a Randomized, Placebo-Controlled, Multi-Center Study Evaluating the Safety and Efficacy of Intravenous Infusion of CAP-1002 – – The Study Leverages Capricor’s Lead Asset, CAP-1002 Technology – LOS ANGELES, Aug. 25, ...

Capricor Therapeutics, Inc. (CAPR) Q2 2020 Earnings Conference Call August 06, 2020, 16:30 ET Company Participants Anthony Bergmann - CFO & Corporate Treasurer Linda Marbán - Co-Founder, President, CEO & Director Conference Call Participants Naureen Quibria - Max...

Gainers:  Conduent (NASDAQ: CNDT ) +75% . More news on: Conduent Incorporated, OpGen, Inc., Groupon, Inc., Stocks on the move, , Read more ...

Capricor Therapeutics (NASDAQ: CAPR ) : Q2 GAAP EPS of -$0.23 beats by $0.11 . More news on: Capricor Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

Exosome Platform for COVID-19 -Novel Multivalent Exosome mRNA and VLP Vaccine Candidates Underway in Animal Studies- -Preclinical Data Shows Positive Antibody Response- CAP-1002 for COVID-19 -Expanded Access Emergency Use Series Published in Peer Reviewed Journal- -Randomiz...

Sonnet BioTherapeutics (NASDAQ: SONN ) +118% . More news on: Sonnet BioTherapeutics Holdings, Inc., electroCore, Inc., Applied DNA Sciences, Inc., Stocks on the move, , Read more ...